DDInter130 DDInter1331
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Atenolol {u} (Compound) resembles {v} (Compound) Betaxolol
Betaxolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Betaxolol
Betaxolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Procarbazine
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Oxprenolol {u} (Compound) resembles {v} (Compound) Betaxolol
Betaxolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol {u} (Compound) resembles {v} (Compound) Procarbazine
Procarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Atenolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Olodaterol
Atenolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Procarbazine (Compound) and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Oxprenolol (Compound) and Oxprenolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Atenolol (Compound) resembles Procarbazine (Compound) and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol